Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

According to the recently published report 'Neuropeptide Y Receptor Type 2 - Drugs In Development, 2022'; Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor.

The report 'Neuropeptide Y Receptor Type 2 - Drugs In Development, 2022' outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity and Epilepsy.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
  • The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Overview
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Companies Involved in Therapeutics Development
Gila Therapeutics Inc
Spark Therapeutics Inc
Takeda Pharmaceutical Co Ltd
XL-protein GmbH
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Drug Profiles
CG-01 – Drug Profile
Product Description
Mechanism Of Action
History of Events
GT-002 – Drug Profile
Product Description
Mechanism Of Action
GT-01 – Drug Profile
Product Description
Mechanism Of Action
History of Events
PYY-1119 – Drug Profile
Product Description
Mechanism Of Action
History of Events
XL-310 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Dormant Products
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Discontinued Products
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Product Development Milestones
Featured News & Press Releases
Feb 11, 2022: CombiGene’s CEO gives business development update
Jan 17, 2022: GMP production of CG01 made available for preclinical studies planned to enable first in human study
Dec 16, 2021: CombiGene and Spark Therapeutics plan to expand the clinical development program to include the U.S. as well as Europe
Nov 04, 2021: BioStock: CombiGene are looking for broader opportunities
Oct 22, 2021: CombiGene’s scientific founders talk about the quantum leap that the epilepsy project CG01 is about to take
Jul 28, 2021: Patent approved in the U.S. and Russia for CombiGenes gene therapy candidate CG01
Jul 26, 2021: CombiGene initiates GMP production of CG01 for the first-in-human study
Jun 30, 2021: BioStock: CombiGene announces several milestones for CG01
Jun 28, 2021: CombiGene and Neurochase begin work to optimize the administration of CG01
Jun 23, 2021: GMP plasmids released – Ready to start GMP production of CG01
Mar 04, 2021: BioStock: CombiGene advances preclinically and recruits post-doc
Mar 01, 2021: The material from the first large-scale production of CG01 is now released for use in the final parts of the preclinical program
Feb 09, 2021: Interview in BioStock, CombiGene on the International Epilepsy Day and the pharmaceutical authorities’ positive response
Feb 03, 2021: Response from the Swedish and UK Pharmaceutical Regulatory Authorities confirms CombiGene’s plan for CG01’s final preclinical studies
Jan 18, 2021: With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development by Stage of Development, 2022
Table 2: Number of Products under Development by Therapy Areas, 2022
Table 3: Number of Products under Development by Indication, 2022
Table 4: Number of Products under Development by Companies, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Number of Products by Stage and Mechanism of Actions, 2022
Table 7: Number of Products by Stage and Route of Administration, 2022
Table 8: Number of Products by Stage and Molecule Type, 2022
Table 9: Pipeline by Gila Therapeutics Inc, 2022
Table 10: Pipeline by Spark Therapeutics Inc, 2022
Table 11: Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Table 12: Pipeline by XL-protein GmbH, 2022
Table 13: Dormant Projects, 2022
Table 14: Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development by Stage of Development, 2022
Figure 2: Number of Products under Development by Therapy Areas, 2022
Figure 3: Number of Products under Development by Indications, 2022
Figure 4: Number of Products by Stage and Mechanism of Actions, 2022
Figure 5: Number of Products by Stage and Route of Administration, 2022
Figure 6: Number of Products by Molecule Types, 2022
Figure 7: Number of Products by Stage and Molecule Types, 2022
"

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings